SI
BMRN icon

Sofinnova Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sofinnova Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.5M Sell
358,568
-423,414
-54% -$23.2M 1.06% 26
2026
Q1 		$44.2M Buy
781,982
+84,849
+12% +$4.95M 1.68% 18
2025
Q4 		$41.4M Buy
+697,133
New +$38M 1.79% 16
2023
Q2 		– Sell
-359,035
Closed -$34.9M – 56
2023
Q1 		$34.9M Sell
359,035
-35,608
-9% -$3.69M 2.23% 12
2022
Q4 		$40.8M Buy
394,643
+99,893
+34% +$9.38M 2.42% 12
2022
Q3 		$25M Sell
294,750
-6,855
-2% -$610K 1.45% 17
2022
Q2 		$25M Buy
301,605
+125,072
+71% +$9.96M 2.08% 13
2022
Q1 		$13.6M Buy
176,533
+89,211
+102% +$7.46M 1.03% 24
2021
Q4 		$7.71M Buy
+87,322
New +$7.21M 0.45% 48
2021
Q1 		– Sell
-164,545
Closed -$14.4M – 69
2020
Q4 		$14.4M Sell
164,545
-94,108
-36% -$7.46M 0.86% 26
2020
Q3 		$19.7M Buy
258,653
+195,756
+311% +$19.8M 1.46% 17
2020
Q2 		$7.76M Sell
62,897
-177,149
-74% -$17.6M 0.49% 41
2020
Q1 		$20.3M Sell
240,046
-201,826
-46% -$17.4M 1.88% 15
2019
Q4 		$37.4M Buy
441,872
+356,976
+420% +$27M 2.69% 9
2019
Q3 		$5.72M Hold
84,896
– – 0.52% 42
2019
Q2 		$7.27M Buy
84,896
+66,402
+359% +$5.68M 0.67% 35
2019
Q1 		$1.64M Sell
18,494
-122,048
-87% -$11.3M 0.16% 59
2018
Q4 		$12M Buy
+140,542
New +$13.4M 1.49% 19

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Sofinnova Investments's BMRN Position: Q2 2026 in Review

Sofinnova Investments reduced its BioMarin Pharmaceuticals (BMRN) stake by 54% in Q2 2026, selling an estimated $23.2M and leaving 358,568 shares worth $20.5M. The position accounts for 1.06% of the portfolio, ranked #26.

Sofinnova Investments first reported a position in BMRN in Q4 2018 and has held it in 18 quarters since. The position peaked at $44.2M in Q1 2026. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Sofinnova Investments held 358,568 shares of BioMarin Pharmaceuticals worth $20.5M as of Q2 2026.
  • Sofinnova Investments sold 423,414 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $23.2M.
  • BioMarin Pharmaceuticals made up 1.06% of Sofinnova Investments's portfolio in Q2 2026, its #26 holding.
  • Sofinnova Investments first reported a position in BioMarin Pharmaceuticals in Q4 2018 and has held it in 18 quarters since.
  • Sofinnova Investments's BioMarin Pharmaceuticals position peaked at $44.2M in Q1 2026.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.